Drug Design, Development and Therapy (Feb 2021)

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]

  • Cheng SL,
  • Ho ML,
  • Lai YF,
  • Wang HC,
  • Hsu JY,
  • Liu SF,
  • Huang MS,
  • Lee CH,
  • Lin CH,
  • Hang LW,
  • Liu YC,
  • Yang KY,
  • Wang JH

Journal volume & issue
Vol. Volume 15
pp. 515 – 516

Abstract

Read online

Cheng SL, Ho ML, Lai YF, et al. Drug Des Devel Ther. 2020;14:5441–5450.The authors have advised there is an error in the formatting of the paper title on page 5441, the title “Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study” should read “Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-world Effectiveness in pAtients without optimally Controlled asThma (REACT) Study”.The authors have also advised the affiliation list on page 5441 is incorrect.  Read the original article  

Keywords